Definitive Contract 75N91019C00035
Award Date 9/16/19
Potential Completion Date 9/15/23
Potential Value $2M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Mountain View, CA 94040, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nvigen, Inc., a small disadvantaged business and woman-owned manufacturer. The contract is for the development of cell-free tumor DNA (ctDNA) diagnostic enabled by magnetic automation assays, under SBIR Topic 353. The contract has a firm fixed price of $275,261.00 and a completion date of August 18, 2017. The contract does not utilize a set-aside...
- This firm fixed price contract for $455,000 was awarded by the National Institutes of Health National Cancer Institute to Nvigen Inc. of San Jose, California. The contract is for research under SBIR Phase II topic 403 to develop highly accurate single cell sequencing technologies with spatial resolution capabilities for cancer research applications. The work directly responds to the solicitation seeking proposals in cancer imaging, spatial sequencing, intra-tumor sensing, and other related...
- <p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
- This is a $182,050 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanoivd, Inc., a small disadvantaged, woman-owned business. The contract is for TAS::75 0849::TAS and has a total small business set-aside designation. The period of performance runs from the award date of September 30, 2010 through the ultimate completion date of March 30, 2011. Nanoivd, Inc. is the prime contractor, and no subcontractors are mentioned. The contract...
- <p>This is a $779,879.76 definitive contract awarded by the National Cancer Institute, a civilian agency, to Cynvenio Biosystems, Inc., a small disadvantaged business. The contract is for research and development in the biomedical basic research domain and has a total small business set aside. The contract was awarded on September 20, 2013 and has a final completion date of September 19, 2015. The contract is a cost-no-fee type with a fixed-price pricing structure.</p>
- <p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>
- This firm fixed price definitive contract was awarded by the National Institutes of Health National Cancer Institute to Senti Biosciences, Inc., a self-certified small disadvantaged business, for $1,999,993. The contract addresses Topic 414 from the fiscal year 2021 Small Business Innovation Research Program solicitation issued by the Department of Health and Human Services, which sought proposals for synthetic biology gene circuits for cancer therapy. The place of performance is South San...
- This is a $1,199,956.00 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanovector Incorporated. The contract is for "OTHER FUNCTIONS TOPIC 267, MULTIFUNCTIONAL THERAPEUTICS USING ENGINEERED PLANT VIRUS NANOPARTICLES" and was set aside for small businesses. The contract has an ultimate completion date of September 27, 2014 and was awarded on September 28, 2012. This contract appears to be part of the NCI's research and development...
- <p>This is a $1,999,984.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Diacarta, Inc. The contract is for the TOPIC 345 - SBIR PHASE II: RADTOX - MEASURING RADIATION TOXICITY USING CIRCULATING DNA project, which aims to develop a method for measuring radiation toxicity using circulating DNA. The contract has a Firm Fixed Price pricing type and is set to be completed by March 15, 2023.</p>
- This definitive firm fixed price contract was awarded by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, to Digital Nanogenetics LLC on September 17, 2018. With a potential value of $300,000, the contract is associated with the Small Business Innovation Research Program Phase I and has a completion date of September 19, 2019. The contract has a set aside designation for total small businesses and will support research...